Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors

　　1.What It Is

　　Binimetinib(Mektovi)is a reversible MEK1/2 inhibitor.It does not hit BRAF directly—it blocks MEK further downstream in the RAS-RAF-MEK-ERK axis.

　　Standard use is in combination with the BRAF inhibitor encorafenib:

　　encorafenib shuts off mutant BRAF;

　　binimetinib blocks MEK so the signal cannot reroute;

　　dual blockade deepens response and delays resistance.

　　2.Where It Is Used(BRAF Testing First)

　　Unresectable or metastatic melanoma

　　Adults with FDA-approved assay-confirmed BRAF V600E or V600K​mutations,combined with encorafenib.

　　Metastatic NSCLC

　　Adults with confirmed BRAF V600E​mutations,combined with encorafenib.

　　💡Molecular testing is mandatory before starting.If plasma testing is negative but suspicion remains high,reflex to tumor tissue per label to avoid false-negative misses.

　　3.Dosing

　　Recommended:45mg orally twice daily,~12 hours apart;

　　with or without food,consistent timing preferred;

　　used together with encorafenib until progression or unacceptable toxicity;

　　encorafenib dose follows its own prescribing information.

　　Dose adjustments

　　first reduction:usually 30mg twice daily;

　　if 30mg is still intolerable:permanently discontinue;

　　moderate/severe hepatic impairment:start at 30mg twice daily.

　　Do not self-split,skip cycles,or stop arbitrarily.

　　4.Adverse Reactions

　　Common

　　Fatigue,nausea,diarrhea,vomiting,abdominal pain,constipation,cough,dyspnea,rash,musculoskeletal pain,visual disturbance.

　　Serious(active monitoring)

　　cardiac:arrhythmia,myocardial infarction,bleeding;

　　pulmonary:pneumonitis,pleural effusion;

　　ocular:retinal vein occlusion,vision loss;

　　hepatic:transaminase elevation,liver injury;

　　systemic:edema,severe skin reactions.

　　Typical workup:

　　baseline+periodic ECG/echo;

　　ophthalmologic exam for new visual symptoms;

　　LFTs,CPK,CBC;

　　immediate reporting of unexplained bleeding,shortness of breath,or chest pain.

　　5.Mechanism in One Pass

　　BRAF V600 mutations lock the MAPK pathway“accelerator on.”Binimetinib inhibits MEK1/2 to stop ERK phosphorylation;encorafenib cuts off BRAF upstream.Two nodes,one pathway—stronger antitumor activity and slower resistance.

　　6.Special Population Red Lines

　　Pregnancy:fetal harm in animal studies;contraindicated.Patients with reproductive potential must use effective contraception during therapy and for 30 days after last dose.

　　Lactation:avoid breastfeeding during treatment and for≥3 days after last dose.

　　Hepatic:

　　mild impairment:usually no adjustment;

　　moderate/severe:30mg twice daily+closer monitoring.

　　Pediatric:not primary population;specialist judgment only.

　　7.Storage

　　original packaging at 20°C–25°C;

　　short excursions allowed 15°C–30°C;

　　protect from moisture and light.

　　8.One-Line Read

　　Binimetinib is not a lone BRAF fighter—it is the MEK half of a dual-target pair.Right test,right combo,right monitoring.